Aulostm Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic, today presented positive results from its ...

Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety ...

Webcast and replay information for this event will also be available on the Investor Relations section of Medicenna's website at ir.medicenna.com. The replay will be available for 90 days. The Bloom ...

The antibody harnesses the power of interleukin-2 (IL-2) by binding precisely to the portion of IL-2 that binds to CD25, which prevents IL-2 from binding to high-affinity IL-2 receptors on Tregs, ...

The study’s small size limits interpretation, but it remains the largest real-world data available, experts said.

Medicenna Therapeutics Corp. ("Medicenna" or the "Company") , a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, ...

is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and ...